Peer-reviewedCC BYBiomedicines
Prior Ustekinumab Exposure and Ulcerative Colitis Are Associated with Suboptimal Trough Levels in Patients Receiving Advanced-Line Vedolizumab or Ustekinumab for Inflammatory Bowel Disease: A Cross-Sectional Cohort Study
4 affiliations
- 1Paediatric Centre, , 1083 Budapest, Hungary; (P.N.); (A.D.-G.); (N.J.B.); (A.B.); (B.P.); (L.T.); (A.J.S.)
- 2Department of Laboratory Medicine, , 1089 Budapest, Hungary; (K.K.); (B.V.)
- 3Department of Surgery, Transplantation and Gastroenterology, , 1082 Budapest, Hungary;
- 4Department of Internal Medicine and Oncology, , 1083 Budapest, Hungary;
Related
- Exploratory baseline mucosal transcriptomics and vedolizumab response in ulcerative colitis
- Multidimensional Inflammatory Biomarker Profiling in COPD: A Latent Inflammatory Construct Associated with Disease Severity and Exacerbation Burden
- Mapping mitochondria-associated research in inflammatory bowel disease : A bibliometric and network analysis
- FDX1 is associated with CALR abundance and JAK–STAT-related inflammatory signaling in myeloproliferative neoplasms
- Nicotinamide Mononucleotide Is Associated with Attenuation of OGD/R-Induced Pro-Inflammatory Programs in Microglia: Transcriptomic Evidence Converging on the NLRP3 Inflammasome and Lipid-Droplet-Related Molecular Signatures
BibTeX
@article{nagypal2026prior,
title = {{Prior Ustekinumab Exposure and Ulcerative Colitis Are Associated with Suboptimal Trough Levels in Patients Receiving Advanced-Line Vedolizumab or Ustekinumab for Inflammatory Bowel Disease: A Cross-Sectional Cohort Study}},
author = {Petra Nagypál and Krisztián Kovács and Barna Vásárhelyi and Antal Dezsőfi-Gottl and Pál Miheller and Ákos Iliás and Nóra Judit Béres and Anna Balogh and Bence Prehoda and Luca Tóbi and Attila József Szabó and Áron Cseh},
journal = {Biomedicines},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13702429},
note = {CC BY},
}
RIS
TY - JOUR
TI - Prior Ustekinumab Exposure and Ulcerative Colitis Are Associated with Suboptimal Trough Levels in Patients Receiving Advanced-Line Vedolizumab or Ustekinumab for Inflammatory Bowel Disease: A Cross-Sectional Cohort Study
AU - Petra Nagypál
AU - Krisztián Kovács
AU - Barna Vásárhelyi
AU - Antal Dezsőfi-Gottl
AU - Pál Miheller
AU - Ákos Iliás
AU - Nóra Judit Béres
AU - Anna Balogh
AU - Bence Prehoda
AU - Luca Tóbi
AU - Attila József Szabó
AU - Áron Cseh
PY - 2026
DA - 2026/10/01
JO - Biomedicines
UR - https://europepmc.org/article/PMC/PMC13702429
SN - 2227-9059
ER -